Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report discusses a successful treatment of Alopecia Areata with tofacitinib and includes a literature review on the condition's pathophysiology and the mechanism of JAK inhibitors, though it notes the high failure rate of available treatments and absence of FDA-approved options.

This study found that US adolescents with alopecia areata, especially those with alopecia totalis or universalis, experience significantly higher healthcare costs and resource use compared to matched controls.

This study examined phase 3 clinical trial data and found that baricitinib improves hair regrowth in adults with alopecia areata and significant scalp hair loss, with the response varying based on the severity of hair loss at the start of treatment.

This review discusses the economic burden of alopecia areata in adolescents and reports no new results; the authors note that evidence in this area is limited.

This study reported that in Hispanic/Latinx patients with alopecia areata, rheumatoid arthritis was a common autoimmune comorbidity, and gastroesophageal reflux disease was notably more prevalent than in other populations with alopecia areata.

In this study, tofacitinib showed a mixed response in treating refractory alopecia areata, with some patients experiencing complete or partial hair regrowth and others showing no response, particularly those with alopecia universalis.

This case study reports that tofacitinib effectively treated alopecia areata in a patient with Crohn's disease and maintained her Crohn's disease management.

This study found that in patients with alopecia areata, serum granulysin levels decreased significantly after treatment with tofacitinib and correlated with reduced disease severity, suggesting serum granulysin as an indicator of immunological activity and response to therapy.

COVID-19 vaccines have been linked to an increase in hair loss conditions.

This study found that corticosteroids were the most common treatments for alopecia areata in the USA, but the substantial disease burden suggests a need for more effective options.

This study found that patients with alopecia areata had a higher incidence rate of herpes simplex infection compared to matched individuals without the condition.

This study found that platelet-rich plasma treatment increased hair density and reduced inflammation in patients with patchy alopecia areata, but not in a patient with alopecia universalis.

This study found that vitamin D levels in children with autoimmune alopecia were often below optimal, but did not suggest a need for extra vitamin D screening beyond standard practices.

This study found that long-term exposure to particulate matter (PM2.5 and PM10) is associated with an increased risk of developing alopecia areata, with possible involvement of inflammatory pathways, suggesting PM as a modifiable environmental risk factor.

This review compiles current insights into alopecia areata's epidemiology, immune mechanisms, diagnosis, treatment options, including novel JAK inhibitors, and its severe psychosocial impact, while also highlighting emerging research areas.

This review article discusses recent advances in stem cell-based therapies for Alopecia Areata, noting preliminary clinical trials show significant hair regrowth, but emphasizes the need for thorough evaluation of long-term safety and efficacy.

This study identified changes in immune activation, ferroptosis, and structural genes in alopecia areata subtypes, suggesting molecular markers that might help understand disease variability and guide future treatments.

This review explored the relationship between alopecia areata and gut microbiota imbalances, noting potential immune dysregulation due to microbiome alterations. It highlighted promising results from fecal microbiota transplantation in treating alopecia universalis, indicating a need for further research into microbiome-targeted therapies.

In this study, ritlecitinib treatment for 12 and 24 weeks downregulated immunity-related genes and upregulated hair keratin genes in patients with alopecia areata, correlating with scalp hair regrowth response.

This study demonstrated the high effectiveness and safety of tofacitinib, a pan-JAK inhibitor, in treating severe forms of alopecia areata, although it is not yet FDA-approved for this condition.

This study suggests that potent topical corticosteroid occlusion may be a safe and effective treatment option for pediatric patients with severe alopecia areata, although further research is needed on its long-term safety and recurrence.

This report highlights a case of a 35-year-old man developing alopecia universalis following alemtuzumab treatment for multiple sclerosis, suggesting potential links between this medication and drug-induced alopecia areata, though the genetic overlap of the conditions may also play a role.

This study suggests that congenital alopecia areata should be considered for newborns with alopecia, supporting the use of topical corticosteroids as a reasonable initial treatment option based on observed regrowth.

Alopecia areata has a high chance of persisting and relapsing, with a significant risk of total hair loss, especially if it starts in childhood.

This case-control study observed that individuals with alopecia universalis and patchy alopecia areata had a higher frequency of fatty liver compared to controls, though the differences were not statistically significant.

This review discusses genetic conditions linked to complete scalp alopecia in children, identifying six genetic causes, but reports no new clinical results.

This review synthesizes current evidence on alopecia areata, detailing its clinical features, pathogenesis, and treatment options, but does not present new clinical results.

This study found that, among 100 patients with alopecia areata, the most prevalent subtype was patchy alopecia areata, with characteristic trichoscopic features including black dots, yellow dots, and empty hair follicles.

In this retrospective study, tofacitinib was found to be effective and well-tolerated for treating severe alopecia areata, with 77% of patients achieving a clinical response over 4-20 months, though results were more favorable for patients with less extensive hair loss.

Azathioprine may help with severe hair loss, a new topical treatment could counteract hair thinning, and trichoscopy can diagnose hair-pulling disorder effectively.